Casdin Capital SPRY Position
Active9-Fund ConvergenceCasdin Capital held their position in ARS Pharmaceuticals, Inc. (SPRY) in Q4 2025, holding $18.6M worth of shares across 1,600,000 shares.
The position was first reported in Q3 2025 and has been tracked across 2 quarterly 13F filings.
SPRY is a convergence signal: 9 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for Placebo in 75 days (Jun 30, 2026), making the timing of Casdin's position particularly relevant.
Short interest stands at 38.8% of float with 21.2 days to cover, indicating significant bearish positioning against Casdin's long thesis.
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Full company profile →Short Interest
38.8%
21.2 days to cover
Casdin Capital SPRY Position History
Frequently Asked Questions
Does Casdin Capital own SPRY?
Yes. As of Q4 2025, Casdin Capital holds 1,600,000 shares of ARS Pharmaceuticals, Inc. (SPRY) valued at $18.6M. This data comes from their SEC 13F filing.
How many hedge funds own SPRY?
9 specialist biotech hedge funds currently hold SPRY, including RA Capital Management, Deerfield Management, OrbiMed Advisors and 5 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Casdin Capital first buy SPRY?
Casdin Capital's position in SPRY was first reported in Q3 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Casdin Capital's SPRY position increasing or decreasing?
Casdin Capital held their SPRY position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
SPRYCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Casdin CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →